series-b
Stage
1
Investors
About
FABENTECH develops and produces emergency treatments targeting bioterrorism risks and priority emerging infectious diseases using a proprietary platform that generates purified polyclonal antibody fragments to neutralize viruses and toxins.
Explore FABENTECH's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.